𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Measurement error bias in pharmaceutical cost-effectiveness analysis

✍ Scribed by Ian C. Marschner

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
145 KB
Volume
22
Category
Article
ISSN
1524-1904

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Longevity bias in cost-effectiveness ana
Longevity bias in cost-effectiveness analysis
✍ Liqun Liu; Andrew J. Rettenmaier; Thomas R. Saving 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract We use a simple lifetime utility maximization model to study the problem of medical resource allocation. This model leads to a welfare specification with a QALY (quality‐adjusted life‐year) component that captures an individual's preferences over both life expectancy and health status.

Bayesian cost-effectiveness analysis wit
Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane
✍ Miguel A. Negrín; Francisco J. Vázquez-Polo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB 👁 1 views

Cost-effectiveness analysis (CEA) compares the costs and outcomes of two or more technologies. However, there is no consensus about which measure of effectiveness should be used in each analysis. Clinical researchers have to select an appropriate outcome for their purpose, and this choice can have d

Discounting for health effects in cost–b
Discounting for health effects in cost–benefit and cost-effectiveness analysis
✍ Hugh Gravelle; Dave Smith 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract When health effects can be valued in monetary terms, as in cost–benefit analysis, they should be discounted at the same rate as costs. If health effects are measured in quantities (e.g. quality adjusted life years) as in cost‐effectiveness analysis (CEA) and the value of health effects

Genetic counseling program in familial b
Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost-effectiveness ratio
✍ Judith Balmaña; Judit Sanz; Xavier Bonfill; Alfonso Casado; Montse Rué; Ignasi G 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 95 KB 👁 1 views

## Abstract Women with a family history of breast cancer are at increased risk for developing this neoplasm. Starting surveillance more frequently at a younger age than the general population and the possibility of undergoing genetic testing are options for their medical management. We analyzed the

An opportunity cost approach to sample s
An opportunity cost approach to sample size calculation in cost-effectiveness analysis
✍ A. Gafni; S. D. Walter; S. Birch; P. Sendi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract The inclusion of economic evaluations as part of clinical trials has led to concerns about the adequacy of trial sample size to support such analysis. The analytical tool of cost‐effectiveness analysis is the incremental cost‐effectiveness ratio (ICER), which is compared with a threshol